

24 AUG 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



10/505569



(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072129 A1

- (51) International Patent Classification⁷: A61K 38/40, (74) Agent: WESTSWEDEN LAW AB; Box 184, Drakegatan
A61P 9/00 10, S-SE-401 23 Göteborg (SE).
- (21) International Application Number: PCT/SE03/00329 (81) Designated States (*national*): AU, JP, US.
- (22) International Filing Date: 27 February 2003 (27.02.2003) (84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0200598-1 27 February 2002 (27.02.2002) SE Published:
— with international search report
- (71) Applicant and
- (72) Inventor: NORRBY, Klas [SE/SE]; Sundhagsgatan 12, S-SE-414 76 Göteborg (SE). ~~SEX~~.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/072129 A1

(54) Title: PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OR PREVENTION OF VASCULAR DISEASE OR STATES OF TISSUE HYPOPERFUSION WITH HYPOXIC AND/OR ISCHEMIC CONSEQUENCES

(57) Abstract: ABSTRACT Disclosed is the use of a substance selected from the group consisting of human apo-lactoferrin and/or peptides derivable from human lactoferrin and/or natural metabolites of human lactoferrin and/or functionally equivalent analogues of human apo-lactoferrin for the production of a pharmaceutical composition for treatment and/or prevention of a vascular disease and/or states of tissue hypoperfusion with hypoxic and/or ischemic consequences. Also a method for treatment of a vascular disease and/or states of tissue hypoperfusion with hypoxic or ischemic consequences wherein a therapeutically effective amount of a substance selected from the group consisting of human apo-lactoferrin and peptides derivable from human lactoferrin and natural metabolites of human lactoferrin and functionally equivalent analogues of human apo-lactoferrin is administered to a patient in need of said treatment is disclosed.